For course details click on the subject areas shown in menu below. To contact us: +44 1635 866699 info@inspiredpharma.com
Annex 1 2022 Section 6: Utilities

Annex 1 2022 Section 6: Utilities

In this article we expand upon the equipment section but looking at Utilities as described in section 6. The level of control of Utilities such as water, steam, compressed gases and so on depends on risk which should be documented in the contamination control...
Annex 1 2022 Section 5: Equipment

Annex 1 2022 Section 5: Equipment

In the last article, I described the premises requirements for sterile product manufacture. In this article we look at the general requirements for the equipment used in the manufacturing of sterile products. Depending on the complexity of the equipment Annex 1...
Annex 1 2022 Section 3: Pharmaceutical Quality System

Annex 1 2022 Section 3: Pharmaceutical Quality System

In this fourth article I shall explore Section 3, the Pharmaceutical Quality System. This is a short section aimed at highlighting the additional requirements beyond those also required from EU GMP chapter 1. It is important to remind ourselves that Annexes are...
Annex 1 2022 Section 2: Principle

Annex 1 2022 Section 2: Principle

In the last article, I discussed the scope of the latest update to Annex 1. In this article I want to focus on section 2, “Principle”. The fundamental basis upon which Annex 1 is now build is written into the principle and its associated clauses. It covers elements of...
Annex 1 2022 Section 1: Scope

Annex 1 2022 Section 1: Scope

In the first article I summarised the background to the latest update to Annex 1. In this article I want to focus on sections 1, “Scope”. The scope of a document is usually intended to outline the range of application of the document. It can be used to summarise areas...
Annex 1 2022 Section 5: Equipment

Annex 1 2022 Introduction and background to the update

Annex 1 has finally arrived, 25th Aug 2022 saw the publication of Annex 1. Normally, updates to GMP chapters and Annexes have a 6-month lead time for implementation. In the case of the new Annex 1, the lead time is 12 months, except for clause 8.123 relating to...